8 Apr 2016 15:55
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
VEC.L Share News (VEC)
VEC Share
Price
VEC Share
News
VEC Share
Chat
VEC Share
Trades
VEC
Live RNS
VEC Share
Charts
VEC Broker
Ratings
VEC Directors
Deals
VEC Financial
Diary
VEC
Fundamentals
VEC Short
Positions
VEC
Media
VEC.L Information
- There is currently no data for VEC
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Breezhaler better than Seretide, says Vectura
Mon, 05th Sep 2016 07:42
(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of chronic obstructive pulmonary disease flare-ups than Seretide.The FTSE 250 firm said the finding was true across different patient sub-groups.In the new analyses, once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of all exacerbations, regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels and previous inhaled corticosteroid use, versus twice-daily Seretide 50/500 mcg."Specifically, among patients with the severest forms of COPD, Ultibro Breezhaler significantly reduced the rate of exacerbations and improved their health status versus the commonly used ICS/LABA combination," Vectura's board said in the statement."In addition, patients using Ultibro Breezhaler needed less rescue medication during the day."It added that new analyses presented at ERS 2016 also showed that, compared to Seretide, Ultibro Breezhaler was associated with fewer systemic effects, namely impairment of adrenal function, which regulates the natural production of hormones."Ultibro Breezhaler use has previously shown to be associated with significantly fewer cases of pneumonia than the ICS/LABA combination."Vectura said Novartis is presenting over 35 abstracts from across its broad respiratory portfolio at ERS 2016."These new findings further demonstrate the superior efficacy of Ultibro Breezhaler versus Seretide across a range of patient sub-groups and support its use as a steroid-free treatment option for COPD patients at risk of exacerbations," explained Vectura CEO James Ward-Lilley."This, combined with the existing efficacy and safety profile of Ultibro Breezhaler, further confirms our confidence in its outlook."
More News
1 Apr 2016 15:46
Broker tips: ARM, Tate & Lyle, Inchcape
(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura. After another strong set of quarterly results, ARM remains the top pick as Numis
Read more1 Apr 2016 15:34
Numis adds Virgin Money, Derwent and Northgate to 'top picks' list
(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura. After another strong set of quarterly results, ARM remains the top pick as Numis
Read more17 Mar 2016 11:52
Vectura receives support from Skyepharma shareholder
(ShareCast News) - Vectura - which focuses on the development of pharmaceutical therapies for airways diseases - has received a letter of intent from a Skyepharma shareholder supporting the companies' proposed merger. Vectura said River and Mercantile Asset Management, which owns just under 4.8m Sky
Read more16 Mar 2016 12:26
UPDATE 1-Vectura to buy SkyePharma for $620 mln as UK biotech consolidates
* Agreed offer values SkyePharma at 410.15 pence a share * Combined group market value more than 1 billion pounds (Adds more on rationale for deal, comment from CEO) By Ben Hirschler LONDON, March 16 (Reuters) - Respiratory drug specialist Vectura has agreed to buy rival SkyeP
Read more16 Mar 2016 08:55
Skyepharma and Vectura agree merger; Skyepharma swings to profit
(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger. Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma
Read more10 Feb 2016 16:22
Wednesday broker round-up
(ShareCast News) - Virgin Money: Nomura starts coverage at buy with a target of 445p. Domino's Pizza: Credit Suisse upgrades to outperform with a target price of 1100p. BBA Aviation: Goldman Sachs downgrades to neutral with 181p target. Greencore: Societe Generale reiterates hold with a 386p targe
Read more10 Feb 2016 08:43
Milestone payday for Vectura on new asthma therapy
(ShareCast News) - Vectura Group's inhaler and formulation technology received a boost on Wednesday, with the completion of a significant milestone on the development of the VR315 product. The FTSE 250 company confirmed that the clinical study report had been finalised, triggering a cash milestone p
Read more